Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968994 | 0.85 | SCN10A (0.43) | SCN10AEIF4A3 | |
| SCHEMBL24481561 | 0.82 | SCN10A (0.32) | SCN10AEIF4A3 | |
| SCHEMBL264864 | 0.82 | SCN10A (0.38) | SCN10AEIF4A3 | |
| Hydrochloric Acid SCHEMBL263971 | 0.81 | SCN10A (0.37) | SCN10AEIF4A3 | |
| SCHEMBL26999655 | 0.79 | SCN10A (0.48) | SCN10A | |
| SCHEMBL31229266 | 0.77 | PTGS2 (0.45) | — | |
| Bromide SCHEMBL10459584 | 0.76 | CCNC (0.31) | — | |
| SCHEMBL265289 | 0.75 | SCN10A (0.41) | SCN10A | |
| Tert-Butyl Formate SCHEMBL27800473 | 0.73 | TDP1 (0.33) | — | |
| SCHEMBL25562963 | 0.72 | GPR84 (0.36) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | SCN10A 51/4885EIF4A3 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.